Filed under: Amgen Inc (AMGN), Options
Amgen (NYSE: AMGN) closed at $44.24 Thursday.
On 3/13/08, the FDA Oncologic Drugs Advisory Committee (ODAC) is scheduled to review the use of Erythropoiesis stimulation agents, including Aranesp and Procrit, to treat chemotherapy induced anemia.
AMGN March option implied volatility is at 45; April is at 38; above its 26-week average of 32 according to Track Data, suggesting larger price risk.
Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com
Permalink | Email this | Comments
